Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. - Test2 - elhamkhani - TriplyDB

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

http://www.wikidata.org/entity/Q34394747

about

The role of oxidative stress in Parkinson's disease Parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and alpha-synuclein mutations promote Tau protein phosphorylation at Ser262 and destabilize microtubule cytoskeleton in vitro Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodies Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein.Mouse models of Parkinson's disease associated with mitochondrial dysfunction Genetically engineered mouse models of Parkinson's disease Gene-environment interactions in Parkinson's disease: specific evidence in humans and mammalian models Synucleins antagonize endoplasmic reticulum function to modulate dopamine transporter trafficking Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein Age-dependent effects of A53T alpha-synuclein on behavior and dopaminergic function Human A53T α-synuclein causes reversible deficits in mitochondrial function and dynamics in primary mouse cortical neurons Alpha-synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease Parkinson's disease: animal models and dopaminergic cell vulnerability Gene-environment interactions: key to unraveling the mystery of Parkinson's disease Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation alpha-Synuclein produces a long-lasting increase in neurotransmitter release Altered dopamine signaling and MPTP resistance in mice lacking the Parkinson's disease-associated GPR37/parkin-associated endothelin-like receptor Alpha-synuclein involvement in hippocampal synaptic plasticity: role of NO, cGMP, cGK and CaMKII Increased striatal dopamine release and hyperdopaminergic-like behaviour in mice lacking both alpha-synuclein and gamma-synuclein Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the PREDIGT score Animal models of Parkinson's disease: vertebrate genetics Hypokinesia and reduced dopamine levels in zebrafish lacking β- and γ1-synucleins.Genetic mouse models of parkinsonism: strengths and limitations.Stereotaxical infusion of rotenone: a reliable rodent model for Parkinson's disease.A microarray study of MPP+-treated PC12 Cells: Mechanisms of toxicity (MOT) analysis using bioinformatics tools.Neuroanatomical phenotyping in the mouse: the dopaminergic system.Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease.Modulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?Absence of alpha-synuclein affects dopamine metabolism and synaptic markers in the striatum of aging mice.Compounds from an unbiased chemical screen reverse both ER-to-Golgi trafficking defects and mitochondrial dysfunction in Parkinson's disease models Loss of α-Synuclein Does Not Affect Mitochondrial Bioenergetics in Rodent Neurons.Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy The chaperone-like activity of α-synuclein attenuates aggregation of its alternatively spliced isoform, 112-synuclein in vitro: plausible cross-talk between isoforms in protein aggregation.The transgenic overexpression of alpha-synuclein and not its related pathology associates with complex I inhibition.Lysosomal function in macromolecular homeostasis and bioenergetics in Parkinson's disease.Mitochondrial dysfunction in the striatum of aged chronic mouse model of Parkinson's disease.SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease

P2860

Q24307946-1499C3B4-21D3-4900-A4B8-7C1C12962150 Q24311461-50B66E16-34F7-4D01-A698-29871D7E43C4 Q24318474-E5501583-3312-4D2E-BD5B-400857C53F29 Q24537310-62E5091F-596D-4AAC-887E-37A1A01F6670 Q24683089-994B2113-B655-489C-AA75-7990C17228A3 Q26269955-645A9300-CC08-4170-9AFF-62CD19696D4A Q26829851-E6BA3436-B7EE-4000-9BB3-C704744CFBF2 Q26852964-DC790E41-1752-4B4D-93C8-9A266C6E0DDC Q26863375-6CF5C7C1-DA68-41ED-A384-1441431A0C40 Q27310037-5EB9BBC6-4DFF-4DB5-836D-0BB4FC3B8FD0 Q27311396-B1DFB506-1F1C-4630-BB42-A1C138345AC6 Q27330366-099E5686-328C-481D-8C79-3C4BB3D669CB Q27332460-C8658284-B17D-489D-85DF-A4C59F93B828 Q27934988-6DB6E92E-AB4B-428E-A4E1-DEE636D3F13F Q28068464-983DF18B-368A-48B8-8D39-D5C5D6F4111F Q28080503-FE320F42-29EB-491C-BED6-61DE9D6DE2D4 Q28388674-591AA8F4-11DD-4853-82B8-EFF330A524FF Q28477043-15649463-FAA9-4FA0-A18E-753D6732069A Q28510893-ECBF9288-43AE-4CBF-9A89-95EBD8FAF26A Q28588013-74230173-B46D-49EB-813D-9052DDAB25AC Q28591581-62DAE3DF-7066-48A0-9804-B2C1275734B7 Q28593809-3982F0E2-0E49-4DD4-A5DF-4477F5E309DC Q29048624-EB8C6BB4-0866-4227-8D62-8B4775D09A69 Q30429583-5BB6E8B4-2956-44FB-B349-BC21B5554590 Q30504583-51B8301F-E974-41C4-B6EB-C88266FB34C6 Q30537732-01BD5BE4-D319-48EA-ACED-696CDED89EC5 Q30895929-6DA61F89-4A3A-40B5-9DCA-BF7DD9D4BF2E Q33219784-F2BD1C75-0F0D-4992-A61D-277874ABD11F Q33227606-2A4D2E87-E87A-4841-8797-76B143545DEF Q33323265-71766791-E11C-4814-B039-D4EAA20CE9FB Q33392127-35B362DB-24D2-4D0B-9E8A-4F050D6E8A41 Q33394700-0247AF44-FE17-4BF0-932F-A83D8EB208F2 Q33521022-9372179D-4EC8-43DE-899E-C2EE7D0B4FFF Q33617563-95D70382-CE03-4117-8036-77738C0060B9 Q33670282-F8FA58E6-1762-4714-9BDC-595BDA0A8575 Q33707184-0F6BA15B-7F4A-41A6-A80D-22E6CC555C64 Q33748087-E2B6917E-853C-4899-AD0B-E8B899A024BB Q33843073-7F8D8160-8134-4608-A9D7-2FD118D3B2CE Q33868426-385FB715-D2B3-4724-898B-C4D0D6B2161C Q33944220-942AC5A9-E5EB-4D0F-8396-AC1CFD09E5C9

P2860

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

http://www.wikidata.org/entity/Q34394747

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年論文

@yue

2002年論文

@zh-hant

2002年論文

@zh-hk

2002年論文

@zh-mo

2002年論文

@zh-tw

2002年论文

@wuu

name

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@ast

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@en

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@nl

type

label

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@ast

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@en

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@nl

prefLabel

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@ast

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@en

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@nl

P1433

Q34394747-AB9F084A-8EE1-4149-8DA1-B061CFC61EBA

P1476

Q34394747-426A5E16-482B-494A-851B-406FD1848182

P2093

Q34394747-0EBB1A30-970F-4733-ABB0-EB6943145525

Q34394747-11E0486B-254D-43C0-B971-B7A30EB351FD

Q34394747-12FF4972-CEA3-4BDE-993C-84EA7605E160

Q34394747-40405368-3079-4D6B-A782-0C45B8395C06

Q34394747-42CAAA13-2682-497C-B2A5-6C053A80045D

Q34394747-468705DB-E44A-40C3-A6BD-2C63088BA92C

Q34394747-57503DC9-0748-460B-9AAA-1CCFB62AC2E9

Q34394747-5F34711D-8D82-4C81-B6B9-7B72CF40F582

Q34394747-6ADE6F4E-89CB-4CEF-999D-36B9AEB7FD4A

Q34394747-701F54AB-493D-418E-A6F0-09BEA50F27F2

P2860

Q34394747-0358952D-3E99-4B6A-847C-D3AF9B34E7E1

Q34394747-03620251-371D-43C7-BF97-4384EBFD08F7

Q34394747-0891041D-F28C-4C10-ACF7-A7FB43ABC145

Q34394747-145DCA29-469E-49BB-945C-93FCB39A691B

Q34394747-26B9F1F6-F072-47F6-BC63-753A8C28709D

Q34394747-312F3A76-24C7-4C12-9867-2C4796519391

Q34394747-3244FE71-4472-418A-8565-B91CDAE86A1B

Q34394747-3AB18162-50A8-49CB-BD1F-2F0EB0C926AB

Q34394747-4CC5213C-DB87-4A6D-A943-62B43D539E73

Q34394747-51C27528-5E7B-448D-ACAA-630231283F4B

P304

Q34394747-7A9B8194-1FFF-4BD8-A160-F36DA1DE3474

P31

Q34394747-91234137-84F8-44BF-84B4-E342A8551306

P356

Q34394747-57149BAF-EC56-411F-81BA-B69DE08F5176

P407

Q34394747-E6AD864A-9EA3-41B3-941D-3922A890A57D

P433

Q34394747-8F181A65-4420-4962-B0F5-A8778E4CCB00

P478

Q34394747-D5E4B8A9-F568-48E6-84BF-470C8691E562

P50

Q34394747-00F34E36-84F1-4C65-A468-89DB3718916C

Q34394747-1CDDA84E-7277-4D95-97C4-64A2AC0E3437

Q34394747-6DAB0369-72CF-498C-BAAD-A75688854911

Q34394747-D6DBAAAF-D813-47D3-AB17-10C649B49060

P577

Q34394747-A732744D-B7C5-482C-ACEA-668C8B37CD91

P5875

Q34394747-424EC2A5-AC9D-43C8-A17E-0F572EA676E7

P698

Q34394747-E1EE7B66-344C-4685-B5AA-59F55D646B1D

P921

Q34394747-45D4DFCE-5740-4607-B41A-1A45262FF284

Q34394747-76F9E37B-78CC-4C29-B21A-1A2EC68F71EE

P932

Q34394747-CF361057-49FC-46DA-A8B7-9C6E2E80CE02

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.

@en

P2093

Anne-Cecile Trillat

http://www.w3.org/2001/XMLSchema#string

Chao Annie Yuan

http://www.w3.org/2001/XMLSchema#string

Kim Tieu

http://www.w3.org/2001/XMLSchema#string

Kristin E Larsen

http://www.w3.org/2001/XMLSchema#string

Marcelo Rocha

http://www.w3.org/2001/XMLSchema#string

Miquel Vila

http://www.w3.org/2001/XMLSchema#string

Nikolai Kholodilov

http://www.w3.org/2001/XMLSchema#string

Rene Hen

http://www.w3.org/2001/XMLSchema#string

Robert Burke

http://www.w3.org/2001/XMLSchema#string

Roland Staal

http://www.w3.org/2001/XMLSchema#string

P2860

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease

Targeted oncogene activation by site-specific recombination in transgenic mice

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

Alpha-synuclein in Lewy bodies

Regulation of serotonin release in the frontal cortex and ventral hippocampus of homozygous mice lacking 5-HT1B receptors: in vivo microdialysis studies

Synucleins are developmentally expressed, and alpha-synuclein regulates the size of the presynaptic vesicular pool in primary hippocampal neurons

A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporter

Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

P304

14524-14529

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.172514599

http://www.w3.org/2001/XMLSchema#string

P407

P433

22

http://www.w3.org/2001/XMLSchema#string

P478

99

http://www.w3.org/2001/XMLSchema#string

P50

Serge Przedborski

Vernice Jackson-Lewis

Steven M Hersch

P577

2002-10-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

11082802

http://www.w3.org/2001/XMLSchema#string

P698

12376616

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

137916

http://www.w3.org/2001/XMLSchema#string